CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Age-Related Differences in Past or Present Hepatitis C Virus Infection Among People Who Inject Drugs: National Human Immunodeficiency Virus Behavioral Surveillance, 8 US Cities, 2015
-
7 02 2019
-
-
Source: J Infect Dis. 220(3):377-385
[PDF-395.54 KB]
Details:
-
Alternative Title:J Infect Dis
-
Personal Author:
-
Description:Background.
Historically, older people who inject drugs (PWID) have had the highest hepatitis C virus (HCV) burden; however, young PWID now account for recent increases. We assessed factors associated with past or present HCV infection (HCV antibody [anti-HCV] positive) among young (≤35 years) and older (>35 years) PWID.
Methods.
We calculated adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs) to examine sociodemographic and past 12-month injection behaviors associated with HCV infection.
Results.
Of 4094 PWID, 55.2% were anti-HCV positive. Among young PWID, anti-HCV prevalence was 42.1% and associated with ≤high school diploma/General Education Development diploma (GED) (aPR, 1.17 [95% CI, 1.03–1.33]), receptive syringe sharing (aPR, 1.37 [95% CI, 1.21–1.56]), sharing injection equipment (aPR, 1.16 [95% CI, 1.01–1.35]), arrest history (aPR, 1.14 [95% CI, 1.02–1.29]), and injecting speedball (aPR, 1.37 [95% CI, 1.16–1.61]). Among older PWID, anti-HCV prevalence was 62.2% and associated with ≤high school diploma/GED (aPR, 1.08 [95% CI, 1.02–1.15]), sharing injection equipment (aPR, 1.08 [95% CI, 1.02–1.15]), high injection frequency (aPR, 1.16 [95% CI, 1.01–1.34]), and injecting speedball (aPR, 1.09 [95% CI, 1.01–1.16])
Conclusions.
Anti-HCV prevalence is high among PWID and varies with age. Scaling up direct-acting antiviral treatment, syringe service programs, and medication-assisted therapy is critical to mitigating transmission risk and infection burden.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:30915477
-
Pubmed Central ID:PMC11111175
-
Document Type:
-
Funding:
-
Volume:220
-
Issue:3
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
